Inmunometabolismo en esclerosis múltiple : implicaciones genéticas y terapéuticas
Loading...
Download
Official URL
Full text at PDC
Publication date
2025
Defense date
16/10/2024
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citation
Abstract
La esclerosis múltiple (EM) es una enfermedad inflamatoria crónica del sistema nervioso central que afecta alrededor de tres millones de personas a nivel mundial, siendo la prevalencia en España de 125 casos por cada 100.000 habitantes. Presenta gran variabilidad interindividual, pero en general se puede clasificar según su evolución en la forma clínica más frecuente, remitente-recurrente (EMRR), que en casi la mitad de los casos evoluciona a secundaria progresiva (EMSP), y la primaria progresiva (EMPP), que supone el 10-15% del total de casos. La etiología de la EM es desconocida, pero se admite que deriva de la interacción entre factores genéticos y ambientales. Mediante estudios de asociación de genoma completo (GWAS) se han identificado 233 variaciones en un solo nucleótido (SNPs) asociadas al riesgo de padecer EM, muchas de ellas relacionadas con el sistema inmunitario. Estas variantes aisladas no son suficientes para desencadenar la enfermedad, pero su contribución conjunta puede ser significativa y además facilitan la descripción de procesos implicados en la aparición de la enfermedad...
Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous systemthat affects around three million people worldwide, with a prevalence in Spain of 125 cases per 100,000 inhabitants. With great interindividual variability, it can be classified according to its evolution into the most common clinical form, relapsing-remitting (RRMS), which in almost half of the cases evolves into secondary progressive (SPMS), and the primary progressive form (PPMS), which represents the 10-15% of total cases.The etiology of MS is unknown, but it is accepted to derive from the interaction betweengenetic and environmental factors. Through Genome-Wide Association Studies (GWAS),233 Single Nucleotide Polymorphisms (SNPs) have been identified associated with the risk of suffering from MS, many of them related to the immune system. These isolated variants are not enough to trigger the disease, but their joint contribution can be significant and they also facilitate the description of processes involved in the onset of the disease...
Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous systemthat affects around three million people worldwide, with a prevalence in Spain of 125 cases per 100,000 inhabitants. With great interindividual variability, it can be classified according to its evolution into the most common clinical form, relapsing-remitting (RRMS), which in almost half of the cases evolves into secondary progressive (SPMS), and the primary progressive form (PPMS), which represents the 10-15% of total cases.The etiology of MS is unknown, but it is accepted to derive from the interaction betweengenetic and environmental factors. Through Genome-Wide Association Studies (GWAS),233 Single Nucleotide Polymorphisms (SNPs) have been identified associated with the risk of suffering from MS, many of them related to the immune system. These isolated variants are not enough to trigger the disease, but their joint contribution can be significant and they also facilitate the description of processes involved in the onset of the disease...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Farmacia, leída el 16-10-2024